Adaptimmune Therapeutics PLC
ADAPY· OTC
ADAPYAdaptimmune Therapeutics PLC
Filed May 10, 2017 · 10-Q · 40 days after period end · 0001104659-17-031428
| Metric | Q1 2017 | Q1 2016 | Q1 2015 |
|---|---|---|---|
| Revenue | $2.86M | $2.92M | $2.73M |
| Net Income | -$21.78M | -$15.58M | -$1.95M |
| EPS Diluted | -$0.05 | -$0.04 | -$0.05 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Adaptimmune Therapeutics PLC · CIK 1621227 · Engraved from SEC EDGAR
ended Mar 31, 2017 · filed May 10, 2017 · 40 d after period end
